目次

Table of Content

1. Introduction to Bispecific Antibody
1.1 Overview
1.2 Clinical Advancement of Bispecific Antibodies

2. Bispecific Antibodies Combination Strategies
2.1 Chemotherapies
2.2 Targeted Therapies
2.3 Immunotherapies
2.4 Radiotherapy

3. Commercially Approved Bispecific Antibodies Insight
3.1 Company, Indication, Location and MOA
3.2 Bispecific Antibodies Granted FDA and EMA Designations

4. Bispecific Antibodies Proprietary Platforms

5. Global and Regional Bispecific Antibody Market Outlook
5.1 Yearly and Quarterly Sales Insight (2019 to 2023)
5.2 Approved Bispecific Antibodies Reimbursement Policy
5.3 Global Bispecific Antibody Market Forecast 2029

6. Global Bispecific Antibody Market Trends By Region
6.1 US
6.2 Europe
6.3 China
6.4 UK
6.5 Japan
6.6 South Korea
6.7 Australia
6.8 Canada
6.9 Latin America

7. Global Bispecific Antibodies Research and Market Trends by Indications
7.1 Lymphoma
7.2 Multiple Myeloma
7.3 Leukemia
7.4 Lung Cancer
7.5 Melanoma
7.6 Blood Disorders
7.7 Gastrointestinal Cancers
7.8 Other Cancers
7.9 Autoimmune and Inflammatory Diseases
7.10 Microbial Diseases
7.11 Ocular Diseases

8. Global Bispecific Antibodies Clinical Trials Overview
8.1 By Phase
8.2 By Country/Region
8.3 By Company
8.4 By Indication
8.5 By Priority Status
8.6 Patient Segment

9. Blincyto - Clinical, Patent, Pricing and Sales Insight
9.1 Overview and Patent Insight
9.2 Pricing and Dosage Analysis
9.3 Sales Analysis

10. Hemlibra - Clinical, Patent, Pricing and Sales Insight
10.1 Overview
10.2 Pricing and Dosage Insight
10.3 Sales Analysis

11. Rybrevant - Clinical, Patent and Pricing Insight
11.1 Overview
11.2 Pricing and Dosage Insight

12. Kimmtrak - Clinical, Patent, Pricing and Sales Insight
12.1 Overview
12.2 Pricing and Dosage Insight
12.3 Sales Analysis

13. Vabysmo - Clinical, Patent, Pricing and Sales Insight
13.1 Overview
13.2 Pricing and Dosage Insight
13.3 Sales Analysis

14. Lunsumio - Clinical, Patent, Pricing and Sales Insight
14.1 Overview and Patent Insight
14.2 Pricing and Dosage Insight
14.3 Sales Analysis

15. Cadonilimab - Clinical and Sales Insight

16. Tecvayli - Clinical, Patent and Pricing Insight
16.1 Overview and Patent Insight
16.2 Pricing and Dosage Insight

17. Columvi - Clinical, Patent, Pricing and Sales Insight
17.1 Overview and Patent Insight
17.2 Pricing and Dosage Insight
17.3 Sales Analysis

18. Epkinly - Clinical, Patent, Pricing and Sales Insight
18.1 Overview
18.2 Pricing and Dosage Insight
18.3 Sales Analysis

19. Talvey - Clinical, Patent and Pricing Insight
19.1 Overview and Patent Insight
19.2 Pricing and Dosage Insight

20. Elrexfio - Clinical, Patent and Pricing Insight
20.1 Overview
20.2 Pricing and Dosage Insight

21. Global Bispecific Antibodies Clinical Trials By Company, Indication and Phase
21.1 Research
21.2 Preclinical
21.3 Phase-I
21.4 Phase-I/II
21.5 Phase-II
21.6 Phase-II/III
21.7 Phase-III
21.8 Preregistration
21.9 Registered

22. Marketed Bispecific Antibodies Clinical Insight By Company, Country and Indication

23. Competitive Landscape
23.1 ABL Bio
23.2 Abzyme Therapeutics
23.3 Affimed Therapeutics
23.4 Akeso Biopharma
23.5 Alligator Bioscience
23.6 Amgen
23.7 Antibody Therapeutics
23.8 APITBIO
23.9 Aptevo Therapeutics
23.10 Astellas Pharma
23.11 AstraZeneca
23.12 BioAtla
23.13 Biosion
23.14 Biotheus
23.15 BJ Bioscience
23.16 EpimAb Biotherapeutics
23.17 FutureGen Biopharmaceutical
23.18 Genentech
23.19 Genmab
23.20 Gensun Biopharma
23.21 Harbour BioMed
23.22 IGM Biosciences
23.23 I-MAB Biopharma
23.24 ImmuneOnco Biopharma
23.25 ImmunoPrecise Antibodies
23.26 Innovent Biologics
23.27 Invenra
23.28 Janssen Research and Development
23.29 Kenjockety Biotechnology
23.30 LaNova Medicines Limited
23.31 Light Chain Bioscience
23.32 Linton Pharm
23.33 Lyvgen Biopharma
23.34 MacroGenics
23.35 Merus
23.36 NovaRock Biotherapeutics
23.37 Pfizer
23.38 Phanes Therapeutics
23.39 Prestige BioPharma
23.40 Regeneron Pharmaceuticals
23.41 Revitope
23.42 Roche
23.43 Virtuoso Therapeutics
23.44 Xencor
23.45 Y-Biologics
23.46 Zhejiang Shimai Pharmaceutical
23.47 Zymeworks

List of Figures
Figure 1-1: Bispecific Antibodies - Advantages
Figure 2-1: Antibody-Chemotherapy Combination - Advantages
Figure 2-2: Antibody-Chemotherapy Combination - Impending Challenges
Figure 3-1: Blincyto - Mechanism of Action
Figure 3-2: Hemlibra - Mechanism of Action
Figure 3-3: Rybrevant - Mechanism of Action
Figure 3-4: Regulatory Designations - Benefits
Figure 4-1: Multiclonics - Distinctive Characteristics
Figure 4-2: Biclonics - Format
Figure 4-3: ADAPTIR Bispecific Structure
Figure 4-4: ADAPTIR-FLEX
Figure 4-5: BEAT Platform - Multispecific Antibodies
Figure 4-6: FIT-Ig - Proprietary Bispecific Platform
Figure 4-7: BiClone format
Figure 4-8: BioAtla CABs - Features
Figure 4-9: BioAtla CABs - Benefits
Figure 4-10: IMBiologic Bispecific Antibodies - Strategy
Figure 4-11: IMBiologic Bispecific Antibodies - Mechanism of Action
Figure 4-12: Novel HBICE
Figure 4-13: HBICE - Mechanism of Action
Figure 4-14: HBICE - Mechanism of Action
Figure 4-15: Phanes Therapeutics - PACbody Platform
Figure 4-16: Phanes Therapeutics - SPECpair Platform
Figure 4-17: Phanes Therapeutics - ATACCbody
Figure 4-18: Numab Therapeutics - Technology
Figure 4-19: Grabody I Platform - Mechanism of Action
Figure 4-20: Grabody I Platform - Mechanism of Action
Figure 4-21: 3-Step DuoBody Production Process
Figure 4-22: DuoHexaBody Molecules - Schematic
Figure 4-23: iTAb - Patented Structure
Figure 4-24: iTAb - Mechanism of Action
Figure 4-25: Synimmune - Proprietary Bispecific Antibody Format
Figure 4-26: BiTE - Structure
Figure 4-27: BiTE Molecule
Figure 4-28: Sanyou Super Trillion Common Light Chain Antibody Discovery Platform
Figure 4-29: ALiCE - Characteristics
Figure 4-30: ALiCE - Schematic Diagram and Mechanism of Action
Figure 4-31: Abz2 Bispecific Platform
Figure 4-32: Abz2 Bispecifics - Benefits
Figure 4-33: Neo-X-Prime Bispecific Mechanism
Figure 4-34: B-Body Bispecific Antibody - Structre
Figure 4-35: xLinkBsAb - Structure
Figure 4-36: PrecisionGATE Bispecific Antibody - Structure
Figure 5-1: Global - Annual Bispecific Antibody Market (US$ Million), 2019-2023
Figure 5-2: Global - Quarterly Bispecific Antibody Market (US$ Million), 2023
Figure 5-3: Global - Annual Bispecific Antibodies Market by Drug (US$ Million), 2023
Figure 5-4: Global - Bispecific Antibodies Market Shares by Drugs (%), 2023
Figure 5-5: Global - Annual Bispecific Antibody Market by Region (US$ Billion), 2023
Figure 5-6: Global - Bispecific Antibody Market Shares by Region (%), 2023
Figure 5-7: Global - Annual Bispecific Antibodies Sales by Drugs (US$ Million), 2022
Figure 5-8: Global - Bispecific Antibodies Market Shares by Drugs (%), 2022
Figure 5-9: Global - Bispecific Antibody Market by Region (US$ Million), 2022
Figure 5-10: Global - Bispecific Antibody Market Shares by Region (%), 2022
Figure 5-11: US - Annual Bispecific Antibody Market Value (US$ Million), 2019-2023
Figure 5-12: ROW - Global Bispecific Antibody Market Value (US$ Million), 2019-2023
Figure 5-13: US - Quarterly Bispecific Antibodies Market (US$ Million), 2023
Figure 5-14: ROW - Quarterly Bispecific Antibodies Market (US$ Million), 2023
Figure 5-15: Blincyto - Total Treatment Cost and Reimbursement Cost
Figure 5-16: Blincyto - In Pocket and Out of Pocket Cost of Treatment
Figure 5-17: Hemlibra - Total Treatment Cost and Reimbursement Cost
Figure 5-18: Hemlibra - In Pocket and Out of Pocket Cost of Treatment
Figure 5-19: Rybrevant - Maximum Coverage by Medicaid (US$), 2023
Figure 5-20: Rybrevant - Maximum Coverage by Private Insurance Coverage (US$), 2021
Figure 5-21: Vabysmo - Total Treatment Cost and Reimbursement Cost
Figure 5-22: Vabysmo - In Pocket and Out of Pocket Cost of Treatment
Figure 5-23: Global - Bispecific Antibody Market Opportunity Assessment (US$ Billion), 2024 - 2029
Figure 6-1: US - Bispecific Antibodies Approval
Figure 6-2: Blincyto - US v/s ROW Sales (US$ Million), 2023
Figure 6-3: Blincyto - US v/s ROW Shares (%), 2023
Figure 6-4: Blincyto - US v/s ROW Sales (US$ Million), 2022
Figure 6-5: Blincyto - US v/s ROW Shares (%), 2022
Figure 6-6: Hemlibra - US v/s ROW Sales (US$ Million), 2023
Figure 6-7: Hemlibra - US v/s ROW Shares (%), 2023
Figure 6-8: Hemlibra - US v/s ROW Sales (US$ Million), 2022
Figure 6-9: Hemlibra - US v/s ROW Shares (%), 2022
Figure 6-10: Global - US v/s ROW in Bispecific Antibodies Market (US$ Million), 2023
Figure 6-11: Global - US v/s ROW Shares in Bispecific Antibodies Market (%), 2023
Figure 6-12: Global - US v/s ROW in Bispecific Antibodies Market (US$ Million), 2022
Figure 6-13: Global - US v/s ROW Shares in Bispecific Antibodies Market (%), 2022
Figure 6-14: Blincyto - US Patent Filing and Expiration Year
Figure 6-15: Blincyto - EU Patent Expiration
Figure 6-16: Vabysmo - Canada Patent Numbers Expiration and Approval Year
Figure 6-17: Hemlibra - Canada Patent Numbers Approval and Expiration Year
Figure 6-18: Rybrevant - Canada Patent Numbers Approval and Expiration Year
Figure 6-19: Kimmtrak - Canada Patent Number Approval and Expiration Year
Figure 7-1: Bispecific Antibodies - Advantages
Figure 7-2: TG-1801 Phase 1 Study - Initiation and Completion Year
Figure 7-3: Bispecific Antibodies - Future Opportunities
Figure 7-4: Mim8 Phase 3 (NCT05053139) Study - Initiation and Completion Year
Figure 7-5: Mim8 Phase 3 (NCT05878938) Study - Initiation and Completion Year
Figure 7-6: NXT007 Phase 1/2 (NCT05987449) Study - Initiation and Completion Year
Figure 7-7: HMB-001 Phase 1/2 (NCT06211634) Study - Initiation and Completion Year
Figure 7-8: REGN4018 Phase 1/2 (NCT03564340) Study - Initiation and Completion Year
Figure 7-9: PRV-3279 Phase 2 (NCT05087628) Study - Initiation and Completion Year
Figure 8-1: Global - Bispecific Antibodies Clinical Pipeline by Phase (Numbers), 2023
Figure 8-2: Global - Bispecific Antibodies in Clinical Pipeline by Country (Numbers), 2024 till 2029
Figure 8-3: Global - Bispecific Antibodies in Clinical Pipeline by Company (Numbers), 2024 till 2029
Figure 8-4: Global - Bispecific Antibodies in Clinical Pipeline by Indication (Numbers), 2023 till 2029
Figure 8-5: Global - Bispecific Antibodies in Clinical Pipeline by Orphan Status (Numbers), 2023 till 2029
Figure 8-6: Global - Bispecific Antibodies in Clinical Pipeline by Patient Segment (Numbers), 2023 till 2029
Figure 9-1: Blincyto - Approval Year by Region
Figure 9-2: Blincyto - Patent Filing and Expiration Year
Figure 9-3: Blincyto - Treatment Regimen Cycles (Weeks)
Figure 9-4: Blincyto - Duration of Treatment Phase and Resting Phase in Induction and Consolidation Cycles for Treatment of MRD-Positive B-cell precursor (Days)
Figure 9-5: Blincyto - Cost of Single Cycle and Treatment Course for the Treatment of MRD-positive B-cell Precursor ALL
Figure 9-6: Blincyto - Recommended Number of Induction and Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL
Figure 9-7: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle and Full Treatment for Relapsed B-Cell Precursor ALL (Weeks)
Figure 9-8: Blincyto - Cost of Single Cycle and Treatment Course for Treatment for Relapsed B-Cell Precursor ALL
Figure 9-9: Global - Blincyto Sales (US$ Million), 2019-2023
Figure 9-10: Global - Blincyto Sales (US$ Million), Q1 - Q4’2023
Figure 9-11: Blincyto - US v/s ROW Sales (US$ Million), 2023
Figure 9-12: Global - Blincyto Sales by Region (%), 2023
Figure 9-13: US - Blincyto Sales (US$ Million), Q1 - Q4’2023
Figure 9-14: ROW - Blincyto Sales (US$ Million), Q1 - Q4’2023
Figure 9-15: US - Blincyto Sales ((US$ Million), 2019-2023
Figure 9-16: ROW - Blincyto Sales (US$ Million), 2019-2023
Figure 10-1: Hemlibra - Approval Years by Region
Figure 10-2: Hemlibra - Cost per Unit and Supply of 150 mg/mL Subcutaneous Injection (US$), February’2024
Figure 10-3: Hemlibra - Recommended Loading and Maintenance Dose for Treatment of Hemophilia (mg/kg/Week)
Figure 10-4: Global - Hemlibra Sales (US$ Million), 2019-2023
Figure 10-5: US - Hemlibra Sales (US$ Million), 2019-2023
Figure 10-6: Europe - Hemlibra Sales (US$ Million), 2019-2023
Figure 10-7: Japan - Hemlibra Sales (US$ Million), 2019-2023
Figure 10-8: ROW - Hemlibra Sales (US$ Million), 2019-2023
Figure 10-9: Global - US v/s ROW Sales (US$ Million), 2023
Figure 10-10: Global - Hemlibra Annual Sales by Region (US$ Million), 2023
Figure 10-11: Global - Hemlibra Sales by Region (%), 2023
Figure 10-12: Global - Hemlibra Sales (US$ Million), Q1 - Q4’2023
Figure 10-13: US - Hemlibra Sales (US$ Million), Q1 - Q4’2023
Figure 10-14: Europe - Hemlibra Sales (US$ Million), Q1 - Q4’2023
Figure 10-15: Japan - Hemlibra Sales (US$ Million), Q1 - Q4’2023
Figure 10-16: ROW - Hemlibra Sales (US$/ US$ Million), Q1 - Q4’2023
Figure 11-1: Rybrevant - Price per Unit and Supply of Intravenous Solution (US$), February’2024
Figure 11-2: Rybrevant - Recommended Dose Per Cycle by Body Weight (mg)
Figure 11-3: Rybrevant - Dose Reduction in Patients with Weight less than 80 kg (mg)
Figure 11-4: Rybrevant - Dose Reduction in Patients with Weight more than 80 Kg (mg)
Figure 12-1: Kimmtrak - Approval Year by Region
Figure 12-2: Kimmtrak - Cost Per Unit and Per Vial (US$), February’2024
Figure 12-3: Global - Annual Kimmtrak Sales (US$ Million), 2021-2023
Figure 12-4: Global - Quarterly Kimmtrak Sales (US$ Million), 2023
Figure 12-5: Kimmtrak - Sales by Region (US$ Million), 2023
Figure 12-6: Kimmtrak - US v/s ROW Market Shares (US$ Million), 2023
Figure 12-7: Kimmtrak - US v/s ROW Market Shares (%), 2023
Figure 12-8: US - Quarterly Kimmtrak Sales (US$ Million), 2023
Figure 12-9: EU - Quarterly Kimmtrak Sales (US$ Million), 2023
Figure 12-10 ROW - Quarterly Kimmtrak Sales (US$ Million), 2023
Figure 13-1: Vabysmo - Approval Year by Region
Figure 13-2: Vabysmo - Price per Unit and Supply of Intravitreal Solution (US$), February’2024
Figure 13-3: Global - Vabysmo Sales (US$ Million), 2022-2023
Figure 13-4: Global - Vabysmo US v/s ROW Sales (US$ Million), 2023
Figure 13-5: Global - Vabysmo Annual Sales by Region (US$ Million), 2023
Figure 13-6: Global - Vabysmo Annual Sales by Region (%), 2023
Figure 13-7: US - Vabysmo Sales (US$ Million), 2022-2023
Figure 13-8: Europe - Vabysmo Sales (US$ Million), 2022-2023
Figure 13-9: Japan - Vabysmo Sales (US$ Million), 2022-2023
Figure 13-10: ROW - Vabysmo Sales (US$ Million), 2022-2023
Figure 13-11: Global - Vabysmo Sales (US$ Million), Q1 - Q4’2023
Figure 13-12: US - Vabysmo Sales (US$ Million), Q1 - Q4’2023
Figure 13-13: Europe - Vabysmo Sales (US$ Million), Q1 - Q4’2023
Figure 13-14: Japan - Vabysmo Sales (US$ Million), Q1 - Q4’2023
Figure 13-15: ROW - Vabysmo Sales (US$ Million), Q1 - Q4’2023
Figure 14-1: Lunsumio - Approval Years by Region
Figure 14-2: US - Price per Unit and Supply of Lunsumio Intravenous Solution (US$), February’2024
Figure 14-3: EU - Price per Unit and Supply of Lunsumio Intravenous Solution (US$), February’2024
Figure 14-4: Global - Lunsumio Sales (US$ Million), 2022-2023
Figure 14-5: US - Lunsumio Sales (US$ Million), 2022-2023
Figure 14-6: Europe - Lunsumio Sales (US$ Million), 2022-2023
Figure 14-7: Global - Lunsumio Annual Sales by Region (US$ Million), 2023
Figure 14-8: Global - Lunsumio Annual Sales by Region (%), 2023
Figure 14-9:- Global - Lunsumio Sales (US$ Million), Q1 - Q4’2023
Figure 14-10: US - Lunsumio Sales (US$ Million), Q1 - Q4’2023
Figure 14-11: Europe - Lunsumio Sales (US$ Million), Q1 - Q4’2023
Figure 15-1: Annual - Cadonilimab Sales (US$ Million), H2’2022 and H1’2023
Figure 16-1: Tecvayli - Approval Years by Region
Figure 16-2: Tecvayli - Patent Acceptance and Expiration Years
Figure 16-3: US - Cost per Unit and Supply of Tecvayli Subcutaneous Solution (US$), February’2024
Figure 16-4: EU - Cost per Unit and Supply of Tecvayli Subcutaneous Solution (US$), February’2024
Figure 17-1: Columvi - Approval Year by Region
Figure 17-2: US - Price per Unit and Supply of Columvi Intravenous Solution (US$), February’2024
Figure 17-3: EU - Price per Unit and Supply of Columvi Intravenous Solution (US$), February’2024
Figure 17-4: Global - Columvi Sales by Region (US$ Million), 2023
Figure 17-5: Global - Columvi Sales (US$ Million), Q1 - Q4’2023
Figure 17-6: US - Columvi Sales (US$ Million), Q1 - Q4’2023
Figure 17-7: Europe - Columvi Sales (US$ Million), Q1 - Q4’2023
Figure 18-1: Epkinly - Approval Year by Region
Figure 18-2: US - Cost per Unit and Supply of Epkinly Subcutaneous Solution (US$), February’2024
Figure 18-3: EU - Cost per Unit and Supply of Epkinly Subcutaneous Solution (US$), February’2024
Figure 18-4: Global - Epkinly Sales (US$ Million), 2023
Figure 18-5: Global - Epkinly Sales (US$ Million), Q1 - Q4’2023
Figure 19-1: Talvey - Approval Year by Region
Figure 19-2: Talquetamab - FDA and EMA Designation Year
Figure 19-3: Talvey - Patent Acceptance and Expiration Year
Figure 19-4: US - Price per Unit and Supply of Talvey Intravenous Solution (US$), February’2024
Figure 19-5: EU - Price per Unit and Supply of Talvey Intravenous Solution (US$), February’2024
Figure 20-1: Elrexfio - Approval Years by Region
Figure 20-2: Elranatamab - FDA and EMA Designation Years
Figure 20-3: US - Price per Unit and Supply of Elrexfio Subcutaneous Solution (US$), February’2024

List of Tables
Table 2-1: Bispecific Antibody and Chemotherapy Combinations in Clinical Trials
Table 2-2: Bispecific Antibody and Targeted Therapy Combinations in Clinical Trials
Table 2-3: Bispecific Antibody and Immunotherapy Combinations in Clinical Trials
Table 2-4: Bispecific Antibody and Radiotherapy Combinations in Clinical Trials
Table 3-1: Approved Bispecific Antibodies
Table 3-2: US - Bispecific Antibodies with Regulatory Designations
Table 3-3: EU - Bispecific Antibodies with Regulatory Designations
Table 3-4: EU - Bispecific Antibodies with Regulatory Designations
Table 5-1: Epkinly - Billing Unit Application for Doses
Table 5-2: Talvey - Coverage Summary
Table 5-3: Talvey - Coding Summary
Table 5-4: Elrexfio - HCPCS Codes
Table 5-5: Elrexfio - HCPCS modifiers
Table 6-1: US - FDA IND Applications Accepted, February’2024
Table 6-2: EU - Bispecific Antibodies in Late Stage Clinical Trials
Table 6-3: Bispecific Antibodies in Clinical Trials in Latin America
Table 7-1: Lymphoma - Bispecific Antibodies in Clinical Trials
Table 7-2: Multiple Myeloma - Bispecific Antibodies in Clinical Trials
Table 7-3: Leukemia - Bispecific Antibodies in Clinical Trials
Table 7-4: Lung Cancer - Bispecific Antibodies in Clinical Trials
Table 7-5: Melanoma - Bispecific Antibodies in Clinical Trials
Table 7-6: Digestive System Cancers - Bispecific Antibodies in Clinical Trials
Table 7-7: Breast Cancer - Bispecific Antibodies in Clinical Trials
Table 7-8: Gynecological Cancers - Bispecific Antibodies in Clinical Trials
Table 7-9: Gynecological Cancers - Bispecific Antibodies in Clinical Trials
Table 9-1: Blincyto - Active Patents
Table 9-2: Blincyto - Recommended Dosage and Schedule for the Treatment of MRD-positive B-cell Precursor ALL
Table 9-3: Blincyto - Recommended Dosage and Schedule for Treatment of Relapsed or Refractory B-cell Precursor ALL
Table 9-4: Blincyto - Recommended Dosage and Schedule for Treatment of Relapsed or Refractory B-cell Precursor ALL
Table 11-1: Rybrevant - Premedication
Table 11-2: Rybrevant - Dose Reductions for Adverse Reactions
Table 11-3: Rybrevant - Recommended Dosage Modifications for Adverse Reactions
Table 12-1: Kimmtrak - Recommended Dosage for Treatment of Unresectable or Metastatic Uveal Melanoma
Table 12-2: Kimmtrak - Dose Modifications for Adverse Reactions
Table 14-1: Lunsumio - Recommended Treatment Cycles
Table 14-2: Lunsumio - Recommended Premedications
Table 14-3: Lunsumio - Recommendations for Management of Cytokine Release Syndrome
Table 16-1: Tecvayli - Dosing Schedule
Table 16-2: Tecvayli - Recommended Dosage Modifications for Adverse Reactions
Table 17-1: Columvi - Dosing Schedule (21-Day Treatment Cycles)
Table 17-2: Columvi - Premedications to be Administered
Table 17-3: Columvi - Recommendations for Management of Cytokine Release Syndrome
Table 17-4: Columvi - Recommended Dosage Modification for Neurologic Toxicity (Including ICANS)
Table 17-5: Columvi - Recommended Dosage Modifications for Other Adverse Reactions
Table 18-1: Epkinly - Dosage Schedule
Table 18-2: Epkinly - Recommendations for Management of Cytokine Release Syndrome
Table 18-3: Epkinly - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Table 18-4: Epkinly - Recommended Dosage Modifications for Other Adverse Reactions
Table 19-1: Talvey - Weekly Dosing Schedule
Table 19-2: Talvey - Biweekly Dosing Schedule
Table 19-3: Talvey - Recommendations for Management of CRS
Table 19-4: Talvey - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Table 19-5: Talvey - Recommendations for Management of Neurologic Toxicity (excluding ICANS)
Table 19-6: Talvey - Recommended Dosage Modifications for Other Adverse Reactions
Table 20-1: Elrexfio - Dosing Schedule
Table 20-2: Elrexfio - Recommendations for Management of CRS
Table 20-3: Elrexfio - Recommended Dosage Modifications for Other Adverse Reactions